Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP-8121 for Hypothyroidism
NCT05823012Phase 2Completed
- Sponsor
- Xeris Biopharma Holdings, Inc.
- Start
- May 2023
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XP-8121 in hypothyroidism, sponsored by Xeris Biopharma Holdings, Inc.. Started May 2023; status: completed.
02
Drugs
XP-8121
03
Conditions
hypothyroidism
Beyond the preview
Go deeper on NCT05823012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823012.